FM8 476
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 3 , S e p t emb e r 2 0 1 7
389
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical PracticeC.R. Chapple, J. Nazir, Z. Hakimi, S. Bowditch, F. Fatoye, F. Guelfucci, A. Khemiri, E. Siddiqui,
A. Wagg
For chronic conditions such as overactive bladder, long-term adherence is important
to maintain treatment benefit. Persistence with antimuscarinics is a recognised
challenge. This analysis of a UK primary care database demonstrates that
persistence and adherence are significantly greater with mirabegron versus
antimuscarinics.
400
Better Persistence Rates with Mirabegron: Questions RaisedA.J. Wein
402
Qualitative Exploration of the Patient Experience of Underactive BladderA.D. Uren, N. Cotterill, C. Harding, C. Hillary, C. Chapple, M. Klaver, D. Bongaerts, Z. Hakimi, P. Abrams
This study adds to our knowledge of how patients describe the symptoms, signs,
and impact of underactive bladder. A variety of lower urinary tract symptoms were
described which could have a broad impact on quality of life.
408
Towards a Greater Understanding of Underactive BladderM. Fode, J. Sønksen
409
Reply from Authors re: Mikkel Fode, Jens Sønksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408–9A.D. Uren, N. Cotterill, C. Harding, C. Hillary, C. Chapple, M. Klaver, D. Bongaerts, Z. Hakimi, P. Abrams
411
Systematic Review of Immune Checkpoint Inhibition in Urological CancersM. Rijnders, R. de Wit, J.L. Boormans, M.P.J. Lolkema, A.A.M. van der Veldt
As second-line treatment, immune checkpoint inhibitors have changed the
perspectives of patients with advanced urothelial and renal cell cancer. Ongoing
studies, also assessing novel combination strategies, may further enhance efficacy
in earlier treatment lines and disease stages of urological cancers.
424
Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary IncontinenceC.R. Chapple, F. Cruz, X. Deffieux, A.L. Milani, S. Arlandis, W. Artibani, R.M. Bauer, F. Burkhard,
L. Cardozo, D. Castro-Diaz, J.N. Cornu, J. Deprest, A. Gunnemann, M. Gyhagen, J. Heesakkers,
H. Koelbl, S. MacNeil, G. Naumann, J.-P.W.R. Roovers, S. Salvatore, K.-D. Sievert, T. Tarcan,
F. Van der Aa, F. Montorsi, M. Wirth, M. Abdel-Fattah
Contemporary surgical mesh for stress urinary incontinence is appropriate for
adequately assessed and counselled patients, with surgery performed by an
experienced surgeon. Contemporary surgical mesh for pelvic organ prolapse should
be used only in highly selected situations after careful consideration, when no
alternative exists.
432
Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate CancerF. Montorsi, G. Gandaglia, N. Fossati, N. Suardi, C. Pultrone, R. De Groote, Z. Dovey, P. Umari,
A. Gallina, A. Briganti, A. Mottrie
Robot-assisted salvage nodal dissection represents a feasible and effective
technique for the management of patients with nodal recurrence after radical
prostatectomy, where one out of three patients experience biochemical response
after surgery.
439
Salvage Surgery for Nodal Recurrence of Prostate Cancer: Might the Robotic Approach Render an Experimental Procedure More Acceptable?R. Schiavina, L. Bianchi, M. Borghesi, G. Martorana, E. Brunocilla
Incontinence
Reviews
Urothelial Cancer
Voiding Dysfunction
Incontinence
Surgery in Motion